Clinical Trial: A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.

U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07794111) titled 'A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.' on Aug. 26.

Brief Summary: This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Obesity / Overweight

Intervention: DRUG: TQF6422 Injection

TQF6422 injection is an anti-ActRIIA/IIB monoclonal antibody.

DRUG: TQF6422 Placebo

A placebo matching TQF6422 Injection in appearance, dosage form, and route of admi...